Home
Summit Therapeutics

Summit Therapeutics Market Share Analysis for June 2026

Announcements, Financial Reports & Filings SEC Filings Reports

Health > Biotechnology and Pharmaceuticals

Domainsmmttx.com

Year Founded2003

Employees201 - 500

Annual Revenue< $1M

Summit Therapeutics

Summit Therapeutics (including company regionals)

smmttx.com

See more website traffic and engagement information

Total visits to Summit Therapeutics's top domains

Understand Summit Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

smmttx.com23.1K

See more with Sales Intelligence

Avg. visit duration in Summit Therapeutics's top domains

Analyze Summit Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

smmttx.com00:00:23

See more with Sales Intelligence

Avg. pageviews on Summit Therapeutics's top domains

See how Summit Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

smmttx.com1.87

See more with Sales Intelligence

Summit Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

nurixtx.comCompany NameNurix TherapeuticsEmployees201 - 500HQUnited States, California, San FranciscoAnnual revenue$50M - $75MTotal visits47.1KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Summit Therapeutics

These are the website technologies, by industry, used by Summit Therapeutics top domains

Conversion & Analytics (2)

Google Analytics

Marketing (2)

Google Marketing Platform

Mobile (2)

Meta Viewport

Widget (2)

Twemoji

More Technologies

4

See all

News & Signals from Summit Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsSummit Therapeutics Inc. sold assets to Biossil in the amount of $500K on Jul 14th '26.Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic drug candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront.

NewsSummit Therapeutics Inc. hires Jack West as VP of Clinical Development.Dr. Jack West joined Summit Therapeutics as VP of Clinical Development - working on ivonescimab, a bispecific now in front-line trials - so that voice speaks from industry.

NewsSummit Corporation identified as competitor of Bristol-Myers Squibb Co on May 31st '26.As Summit Therapeutics' Chinese partner prepares to reveal data for a key trial at ASCO, analysts consider the impact on rivals Merck, Bristol Myers Squibb and BioNTech.